Jenphar Bangladesh Ltd.
Crizotinib Cancer (oncology)
Originator: Xalkori · Pfizer
| Brand | Strength | Form |
|---|---|---|
| Crizonil | 250 mg capsule | — |
| Crizonil | 250 mg | Capsule |
Dapagliflozin Diabetes & metabolic
Originator: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)
| Brand | Strength | Form |
|---|---|---|
| Dialozin | 5 mg | — |
Ibrutinib Cancer (oncology)
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
| Brand | Strength | Form |
|---|---|---|
| Ibrunib | 140 mg capsule | — |
| Ibrunib | 140 mg | Capsule |
Niraparib Cancer (oncology)
Originator: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)
| Brand | Strength | Form |
|---|---|---|
| Ovaxa | 100 mg capsule | — |
| Ovaxa | 100 mg | Capsule |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form |
|---|---|---|
| Juparib | 150 mg | Tablet |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form |
|---|---|---|
| Tasso | 80 mg tablet | — |
| Tasso | 80 mg | Tablet |
Sofosbuvir/Velpatasvir Antivirals (hepatitis C)
Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)
| Brand | Strength | Form |
|---|---|---|
| Velpacee | 400 mg + 100 mg tablet | — |
| Velpacee | 400 mg+100 mg | Tablet |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
